A New Jersey federal judge has granted an out for drugmakers Celgene and Bristol-Myers Squibb from consolidated antitrust litigation. The case had accused them of delaying the entry of generic competition to their blockbuster cancer treatments. The ruling determined that the conduct alleged by the group of insurer plaintiffs does not constitute anti-competitive behavior. For more details, the original article can be found here.